Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

34.81USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$34.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,425
52-wk High
$68.57
52-wk Low
$28.54

Chart for

About

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $872.76
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  ANIK.OQ Industry Sector
P/E (TTM): 26.41 30.93 32.76
EPS (TTM): 2.25 -- --
ROI: 14.62 15.07 14.61
ROE: 15.11 16.60 16.34

BRIEF-Anika Therapeutics Announces $30 Mln Accelerated Share Repurchase

* ANIKA THERAPEUTICS ANNOUNCES $30 MILLION ACCELERATED SHARE REPURCHASE

May 23 2018

BRIEF-Anika Therapeutics Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S

May 02 2018

BRIEF-Joseph Darling Named CEO And Director Of Anika Therapeutics

* JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS

Mar 05 2018

BRIEF-Anika Q4 Earnings Per Share $0.53

* ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 21 2018

BRIEF-Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology

* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Anika Therapeutics Expands Strategic Collaboration With Institute For Applied Life Sciences

* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:

Jan 24 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.11 --
Novartis AG (NOVN.S) CHF79.98 +1.78
Pfizer Inc. (PFE.N) $37.65 --
Roche Holding Ltd. (ROG.S) CHF233.75 +1.75
Roche Holding Ltd. (RO.S) CHF238.00 +1.20
Merck & Co., Inc. (MRK.N) $62.53 --
Bayer AG (BAYGn.DE) €93.24 -0.17
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.47 +0.63
Abbott Laboratories (ABT.N) $62.80 --

Earnings vs. Estimates